Iceland· IS-EU/1/16/1136/003-004
Cabometyx
A cabozantinib product containing cabozantinibum inn (s)-malat, registered in Iceland by Ipsen Pharma*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Cabozantinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX07 (cabozantinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Cabozantinib · ATC L01EX07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of cabozantinib costs, country by country.
Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cabozantinib · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$570.30
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Cabozantinibum INN (S)-malat
- Manufacturer
- Ipsen Pharma*
- Country
- Iceland (IS)
- ATC code
- L01EX07
- ATC class
- Cabozantinib
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean97591430 stk x1 pakkiISK 798766
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
544 interactions on record for cabozantinib.
Graded by severity as the source publishes them — 360 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cabozantinib · interactions on record
544 records
- 360 severe
- 179 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EX07
Cabozantinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4d2cfc6c-2245-4329-bdc2-0c241c600130 GET /v1/drugs/4d2cfc6c-2245-4329-bdc2-0c241c600130?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EX07",
"marketed": false,
"strength": "40 mg",
"ma_number": "EU/1/16/1136/003-004",
"substance": "Cabozantinibum INN (S)-malat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42622"
}See everything about cabozantinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.